Reaffirms FY25 SG&A expenses view $50M-$60M excluding share-based compensation. Reaffirms FY25 share-based compensation expenses view $18M-$20M; and Non-GAAP Net Income from Operations and Cash Burn in 2025 to be similar to levels incurred in 2024. Both Non-GAAP Net Income from Operations and Cash Burn guidance metrics exclude one-time, non-recurring Revenue and Income items incurred throughout 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH:
- TBPH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Theravance Biopharma price target raised to $25 from $24 at BTIG
- Theravance Biopharma Gains Milestone Payment from Viatris
- Theravance Biopharma announces Viatris approval for Yupelri in China
- Theravance Biopharma initiated with a Buy at JonesResearch